Objective Progress in neoadjuvant therapy for resectable nonsmall cell lung cancer (NSCLC
1) has been stagnant. There have been great achievements in immunotherapy for advanced …

Background In recent years, a series of clinical trials have explored the application of
neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer …

Background Neoadjuvant immunotherapy (nIT) is a rapidly emerging paradigm for
advanced resectable non‐small cell lung cancer (NSCLC). The objectives of this …

Lung cancer is the leading cause of cancer-related deaths worldwide. Patients with
resectable NSCLC are often treated with surgery and adjuvant chemotherapy. However …

Importance To date, no meta-analyses have comprehensively assessed the association of
neoadjuvant chemoimmunotherapy with clinical outcomes in non–small cell lung cancer …

Lung cancer mortality has decreased over the past decade and can be partly attributed to
advances in targeted therapy and immunotherapy. Immune checkpoint inhibitors (ICIs) have …

Lung cancer is the leading cause of cancer-related death worldwide and in China (1).
According to the statistics of the National Cancer Center of China, there were 733,300 new …

Background Currently, immunotherapy is widely used in the treatment of various stages of
non-small cell lung cancer. According to clinical experience and results of previous studies …

Background The recent novel conception of neoadjuvant immunotherapy has generated
interest among surgeons worldwide, especially the lack of experience involving surgical …

Opinion statement While cisplatin-based adjuvant chemotherapy has been the standard of
care for the past two decades, the recent introduction of immunotherapy has heralded an …